A ”Clickable” Probe for Active MGMT in Glioblastoma Demonstrates Two Discrete Populations of MGMT
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A ”Clickable” Probe for Active MGMT in Glioblastoma Demonstrates Two Discrete Populations of MGMT
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 2, Pages 453
Publisher
MDPI AG
Online
2020-02-24
DOI
10.3390/cancers12020453
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PAM-OBG: A monoamine oxidase B specific prodrug that inhibits MGMT and generates DNA interstrand crosslinks, potentiating temozolomide and chemoradiation therapy in intracranial glioblastoma
- (2018) Martyn A. Sharpe et al. Oncotarget
- S-phase Specific Downregulation of Human O 6 -Methylguanine DNA Methyltransferase (MGMT) and its Serendipitous Interactions with PCNA and p21 cip1 Proteins in Glioma Cells
- (2018) AGM Mostofa et al. NEOPLASIA
- Fluorogenic Real-Time Reporters of DNA Repair by MGMT, a Clinical Predictor of Antitumor Drug Response
- (2016) Andrew A. Beharry et al. PLoS One
- Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review)
- (2015) GIULIO CABRINI et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Monoamine oxidase B levels are highly expressed in human gliomas and are correlated with the expression of HiF-1α and with transcription factors Sp1 and Sp3
- (2015) Martyn A. Sharpe et al. Oncotarget
- Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
- (2014) Walter Taal et al. LANCET ONCOLOGY
- Hydrogen peroxide sensing, signaling and regulation of transcription factors
- (2014) H. Susana Marinho et al. Redox Biology
- Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
- (2013) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas
- (2013) C-H Fan et al. Cell Death & Disease
- The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer
- (2013) Emilia Kansanen et al. Redox Biology
- Temozolomide: Mechanisms of Action, Repair and Resistance
- (2011) Jihong Zhang et al. Current Molecular Pharmacology
- Thin layer chromatography-based assay of O6-methylguanine-DNA methyltransferase activity in tissue
- (2010) Cliff Robinson et al. ANALYTICAL BIOCHEMISTRY
- Oxidative stress, inflammation, and cancer: How are they linked?
- (2010) Simone Reuter et al. FREE RADICAL BIOLOGY AND MEDICINE
- MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
- (2009) Michael Weller et al. Nature Reviews Neurology
- Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas
- (2009) Sibille Everhard et al. NEURO-ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation